B2 Thymoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma (NCT07598955) | Beijing Biotech | 2026-03-02 |
Track B2 Thymoma automatically
Every clearance here is in the API, with alerts when new ones post.